Overview

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
0
Participant gender:
All
Summary
This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Brendan Lucey
Collaborator:
Eisai Inc.
Treatments:
Lemborexant
Criteria
Inclusion Criteria:

- Age 60-80 years

- Any sex

- Any race/ethnicity

- Mini-Mental Status Examination score (MMSE) ≥ 27

- Positive plasma amyloid-beta test (i.e., amyloid-positive)

- Pittsburgh Sleep Quality Index >5

Exclusion Criteria:

- Cognitive impairment as determined by history of MMSE < 27

- Inability to speak or understand English

- Any sleep disorders other than insomnia

- No history of moderate-to-severe sleep-disordered breathing and STOP-Bang score > 5

- History or reported symptoms suggestive of restless legs syndrome, narcolepsy or other
sleep disorders

- No more than mild sleep apnea (AHI <16) on PSG

- Sleep schedule outside the range of bedtime 22:00-midnight

- Contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to
lidocaine or disinfectant; prior central nervous system or lower back surgery)

- Cardiovascular disease requiring medication except for controlled hypertension (PI
discretion)

- Stroke

- Hepatic or renal impairment

- Pulmonary disease (PI discretion)

- Type 1 diabetes

- HIV or AIDS

- Neurologic or psychiatric disorder requiring medication (PI discretion)

- Suicidal ideations

- Alcohol or tobacco use (PI discretion)

- Use of sedating medications (PI discretion)

- Inability to get out of bed independently

- In the opinion of the investigator, the participant should be excluded due to an
abnormal physical examination.

- Current pregnancy

- Body Mass Index >35

- History of migraines (PI discretion)

- History of drug abuse in the last 6 months

- History or presence of any clinically significant medical condition, behavioral or
psychiatric disorder (including suicidal ideation), or surgical history based on
medical record or patient report that could affect the safety of the subject or
interfere with study assessments or in the judgment of the PI participant is not a
good candidate.

- Urinary or fecal incontinence

- Concurrently enrolled in another trial of an investigational drug or device